Skip to main content
NIH funding notice RFA-HD-23-018

MPRINT Translational Research Resource Platform (TRRP) (U24 Clinical Trial Not Allowed)

Closed on December 1, 2022.

Posted
August 19, 2022
Close date
December 1, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $833,182 in first-year total cost, median $833,182.

Most frequent study sections

  1. Special Emphasis Panel[ZHD1 DSR-A (50)]1

Most frequent institutions

  1. OHIO STATE UNIVERSITY1
Competing awards under RFA-HD-23-018 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Developing Extracellular Vesicle Based MPRINT Translational Resource Platform for Monitoring Therapeutics Response During Pregnancy1R24HD113024-01COSTANTINE, MAGEDMENON, RAMKUMAROHIO STATE UNIVERSITY, OH$833,182ZHD1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.